Back
Entrada Therapeutics, Inc. Stock Predictions
1.5 Million Users. Zero Hype. Still Private.
*DISCLOSURE: This is a paid advertisement for Immersed Reg A offering and involves risk, including the possible loss of principal. Please read the offering circular and related risks immersed.com
Sell
41
TRDA
Entrada Therapeutics, Inc.
Last Price:
$10.62
Seasonality Move:
-22.18%
7 Day Trial
ALL ACCESS PASS
$
7
Most Pre-IPO Big Tech Shifts Look Like This at the Start
*DISCLOSURE: This is a paid advertisement for Immersed Reg A offering and involves risk, including the possible loss of principal. Please read the offering circular and related risks immersed.comEntrada Therapeutics, Inc. Stock Forecast
-
Over the next 52 weeks, Entrada Therapeutics, Inc. has on average historically risen by 6.7% based on the past 4 years of stock performance.
-
Entrada Therapeutics, Inc. has risen higher in 2 of those 4 years over the subsequent 52-week period, corresponding to a historical accuracy of 50%
-
Is Entrada Therapeutics, Inc. Stock Undervalued?The current Entrada Therapeutics, Inc. [TRDA] share price is $10.60. The Score for TRDA is 41, which is 18% below its historic median score of 50, and infers higher risk than normal.
-
TRDA is currently trading in the 40-50% percentile range relative to its historical Stock Score levels.
Will Entrada Therapeutics, Inc. Stock Go Up Next Year?
-
Over the next 52 weeks, Entrada Therapeutics, Inc. has on average historically risen by 6.7% based on the past 4 years of stock performance.
Entrada Therapeutics, Inc. Stock Rating
Sell
41
Entrada Therapeutics, Inc. (TRDA)
is a Sell
Is Entrada Therapeutics, Inc. overpriced?
-
Entrada Therapeutics, Inc. has risen higher in 2 of those 4 years over the subsequent 52-week period, corresponding to a historical accuracy of 50%
Entrada Therapeutics, Inc. Stock Price History
Stock Information
Stock Info
Exchange:
NASDAQ
Country:
United States
Industry:
Biotechnology
Sector:
Health Care
Type:
stock
Website:
entradatx.com
52-Week Data
52-Week High:
13.82
52-Week Low:
4.93
Prediction Charts
Market Cap:
405.1M
Price in USD:
10.60
Volume:
192.2K
Beta:
-0.12
Technical Analysis
SMA50:
10.69
SMA100:
8.70
SMA200:
7.81
52-Wk Change:
-21.37%
Stock Predictions
-
Is Entrada Therapeutics, Inc. stock public?Yes, Entrada Therapeutics, Inc. is a publicly traded company.
-
What is the Entrada Therapeutics, Inc. stock quote today?The Entrada Therapeutics, Inc. stock price is 10.60 USD today.
-
How to buy Entrada Therapeutics, Inc. stock online?You can buy Entrada Therapeutics, Inc. shares by opening an account at a top tier brokerage firm, such as TD Ameritrade or tastyworks.
14-Day Historical Data
| Date | Opening | Closing | Minimum | Maximum |
|---|---|---|---|---|
| Jan-20 | 10.88 | 10.62 | 11.35 | 10.34 |
| Jan-21 | 10.63 | 11.30 | 11.43 | 10.63 |
| Jan-22 | 11.35 | 11.71 | 12.18 | 11.14 |
| Jan-23 | 11.61 | 11.43 | 12.04 | 11.20 |
| Jan-26 | 11.34 | 11.10 | 11.45 | 10.83 |
| Jan-27 | 11.16 | 11.00 | 11.56 | 10.81 |
| Jan-28 | 11.26 | 11.15 | 11.31 | 10.52 |
| Jan-29 | 11.45 | 11.66 | 11.82 | 11.45 |
| Jan-30 | 11.58 | 11.44 | 11.75 | 11.28 |
| Feb-2 | 11.40 | 11.85 | 12.08 | 11.40 |
| Feb-3 | 11.84 | 11.79 | 12.08 | 11.48 |
| Feb-4 | 11.89 | 10.82 | 12.05 | 10.69 |
| Feb-5 | 10.36 | 10.07 | 10.91 | 9.79 |
| Feb-6 | 10.30 | 10.60 | 10.71 | 10.19 |
Entrada Therapeutics, Inc. Earnings
Entrada Therapeutics, Inc. Earnings Report: Per Share Entrada Therapeutics, Inc. Earnings Q1 Q2 Q3 and Q4 last year and next year.
Entrada Therapeutics, Inc. Forecast Revenue Growth
Entrada Therapeutics, Inc. Stock Analysis: Historical quarterly revenues per share for Entrada Therapeutics, Inc. and historical quarterly revenue growth:
-
Analysts estimate an earnings decrease this quarter of $0.01 per share, a decrease next quarter of $0.00 per share, a decrease this year of $0.50 per share, and a decrease next year of $0.05 per share.
* Entrada Therapeutics, Inc. stock forecasts short-term for next days and weeks may differ from long term prediction for next month and year based on timeline differences.